Jun Matsumoto

7PUBLICATIONS
1CO-AUTHORS
Predictive and prognostic markersMolecular targetsImmunology not elsewhere classifiedCancer therapy (excl. chemotherapy and radiation therapy)Pharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|May 09, 2025
Comprehensive analysis of adverse event profile changes with pertuzumab addition to trastuzumab-based breast cancer therapy: Disproportionality analysis using VigiBase.

Tatsuaki Takeda, Jun Matsumoto, Tomonori Sakai

|Jan 05, 2025
[Precision Medicine for Patients with Renal Cell Carcinoma Based on Drug-metabolizing Enzyme Expression Levels].

Jun Matsumoto

|Apr 17, 2024
Adverse events of nivolumab plus ipilimumab versus nivolumab plus cabozantinib: a real-world pharmacovigilance study.

Yurie Oka, Jun Matsumoto, Tatsuaki Takeda

|Jan 19, 2024
A comparison between the adverse event profiles of patients receiving palbociclib and abemaciclib: analysis of two real-world databases.

Tatsuaki Takeda, Shiho Sugimoto, Jun Matsumoto

|Dec 26, 2022
Significance of UGT1A6, UGT1A9, and UGT2B7 genetic variants and their mRNA expression in the clinical outcome of renal cell carcinoma.

Jun Matsumoto, Anzu Nishimoto, Shogo Watari

|Oct 25, 2019
Effect of CYP3A5*3 genetic variant on the metabolism of direct-acting antivirals in vitro: a different effect on asunaprevir versus daclatasvir and beclabuvir.

Jun Matsumoto, Su Nwe San, Masachika Fujiyoshi

Pageof 2

Frequent Collaborators

2 joint publications

Tatsuaki Takeda